Ingredient or product comparison
Can You Take GHK-Cu Cosmetic Orally: Oral vs Subcutaneous vs Topical Comparison
Before choosing an administration route, it helps to see how each method performs across the variables that determine peptide efficacy: bioavailability, time to peak plasma concentration, duration of effect, dosing precision, and risk profile. Oral (capsule/ta
This source-based comparison does not add ratings or recommend a winner.
- Before choosing an administration route, it helps to see how each method performs across the variables that determine peptide efficacy: bioavailability, time to peak plasma concentration, duration of effect, dosing precision, and risk profile.
- Oral (capsule/tablet)
- 0.5–2%
- Not applicable (insufficient absorption)
- 50–100mg to approach threshold (copper toxicity risk at this dose)
- Room temperature stable but therapeutically irrelevant
- Gastric acid and pepsin degrade peptide bonds; hepatic first-pass metabolism eliminates residual intact compound
- Subcutaneous injection
- 80–95%
- 60–90 minutes
- 0.5–2mg per dose
- Requires refrigeration at 2–8°C post-reconstitution; 28-day use window
- Requires reconstitution technique; injection discomfort; sterile handling
- Topical (cream/serum)
- 5–15% (localized; minimal systemic)
- 2–4 hours (dermal layer; not systemic circulation)
- 0.1–1mg per application (concentration 0.01–0.1% in carrier)
- Room temperature stable in airless pump; light-sensitive
- Limited to dermal penetration depth; does not achieve systemic plasma levels
- The comparison clarifies why research protocols default to subcutaneous delivery when systemic GHK-Cu effects are the target—whether in wound healing models, hair follicle regeneration studies, or anti-inflammatory assays. Topical application works for localized skin effects (collagen density in photoaged skin, for example), but it doesn't produce measurable plasma concentrations. Oral administration fails at both: it doesn't deliver localized tissue concentrations and it doesn't achieve systemic levels.
- One question comes up repeatedly: what if you take GHK-Cu cosmetic orally in enteric-coated capsules designed to resist gastric acid? Enteric coatings delay drug release until the capsule reaches the small intestine at pH 6.0 or higher, protecting acid-labile compounds during gastric transit. This improves oral bioavailability for some peptides—GLP-1 analogs, for instance, show 3–5% bioavailability with enteric coating versus <1% without.
- But enteric coating only solves one problem: gastric acid exposure. It doesn't prevent intestinal peptidase cleavage, and it doesn't force the compound through peptide transporters that weren't designed to carry it. Even with enteric protection, GHK-Cu faces brush border aminopeptidases that hydrolyze the peptide at the intestinal surface before absorption occurs. Published studies on enteric-coated tripeptides rarely exceed 5% bioavailability—still 16- to 20-fold lower than subcutaneous injection. The coating adds formulation cost and regulatory complexity without closing the efficacy gap.